353 related articles for article (PubMed ID: 22446323)
1. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
2. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
3. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.
Giantin M; Aresu L; Benali S; Aricò A; Morello EM; Martano M; Vascellari M; Castagnaro M; Lopparelli RM; Zancanella V; Granato A; Mutinelli F; Dacasto M
J Comp Pathol; 2012 Nov; 147(4):419-29. PubMed ID: 22520817
[TBL] [Abstract][Full Text] [Related]
5. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM
Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979
[TBL] [Abstract][Full Text] [Related]
6. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
7. Production of stem cell factor in canine mast cell tumors.
Amagai Y; Tanaka A; Jung K; Matsuda A; Oida K; Nishikawa S; Jang H; Ishizaka S; Matsuda H
Res Vet Sci; 2014 Feb; 96(1):124-6. PubMed ID: 24269079
[TBL] [Abstract][Full Text] [Related]
8. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors.
Passantino L; Passantino G; Cianciotta A; Ribaud MR; Lo Presti G; Ranieri G; Perillo A
Immunopharmacol Immunotoxicol; 2008; 30(3):609-21. PubMed ID: 18608529
[TBL] [Abstract][Full Text] [Related]
9. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.
Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA
Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022
[TBL] [Abstract][Full Text] [Related]
10. Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.
Takeuchi Y; Fujino Y; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):208-16. PubMed ID: 20591500
[TBL] [Abstract][Full Text] [Related]
11. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
12. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.
Matsuda A; Tanaka A; Amagai Y; Ohmori K; Nishikawa S; Xia Y; Karasawa K; Okamoto N; Oida K; Jang H; Matsuda H
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):321-8. PubMed ID: 21908058
[TBL] [Abstract][Full Text] [Related]
13. Recombinant canine IgE Fc and an IgE Fc-TRAIL fusion protein bind to neoplastic canine mast cells.
Elders RC; Holder A; Smith KC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2014 May; 159(1-2):29-40. PubMed ID: 24690189
[TBL] [Abstract][Full Text] [Related]
14. In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors.
Seung BJ; Cho SH; Kim SH; Bae MK; Lim HY; Sur JH
Vet Comp Oncol; 2021 Mar; 19(1):132-139. PubMed ID: 32926564
[TBL] [Abstract][Full Text] [Related]
15. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
[TBL] [Abstract][Full Text] [Related]
16. p62/Sequestosome-1: Mapping Sites of Protein-Handling Stress in Canine Cutaneous Mast Cell Tumors.
Rich T; Dean RT; Lamm CG; Ramiro-Ibañez F; Stevenson ML; Patterson-Kane JC
Vet Pathol; 2015 Jul; 52(4):621-30. PubMed ID: 25161207
[TBL] [Abstract][Full Text] [Related]
17. The value of immunohistochemical expression of BAX in formulating a prognosis for canine cutaneous mast cell tumours.
Strefezzi Rde F; Kleeb SR; Xavier JG; Fukumasu H; Catão-Dias JL
J Comp Pathol; 2012 May; 146(4):314-9. PubMed ID: 21899858
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin in canine mast cell tumors: decreased expression and altered subcellular localization in Grade 3 tumors.
Mackowiak II; Gentile LB; Chaible LM; Nagamine MK; Guerra JM; Mota EF; Matera JM; Mennecier G; Sanches DS; Dagli ML
Vet J; 2012 Dec; 194(3):405-11. PubMed ID: 22766308
[TBL] [Abstract][Full Text] [Related]
19. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.
Preziosi R; Morini M; Sarli G
J Vet Diagn Invest; 2004 Nov; 16(6):554-61. PubMed ID: 15586571
[TBL] [Abstract][Full Text] [Related]
20. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
Fröberg GK; Lindberg R; Ritter M; Nordlind K
J Comp Pathol; 2009; 141(2-3):89-97. PubMed ID: 19446835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
